DRG Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of AHF hospitalizations for each country, as well as annualized event counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.

DRG Epidemiology’s AHF forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AHF over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In total, DRG Epidemiology forecasts the following AHF patient population:

  • Diagnosed events of AHF.

Note: Coverage may vary by country.

Table of contents

  • Acute Heart Failure - Epidemiology - Europe
    • Introduction
      • Key Updates
      • Event Rate of Acute Heart Failure Hospitalizations per 1,000 People Aged 20+ in 2019 and 2029
      • Relative Sizes of the Contributing Factors to the Trend in AHF Events over the Next Ten Years
    • Epidemiology Data
    • Methods
      • Diagnosed Events
      • Drug-Treated Events
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Acute Heart Failure
      • Risk/Protective Factors
        • Risk/Protective Factors for Acute Heart Failure
      • Bibliography

Author(s): Dr. Ravdeep Kaur, MPH; Lade Ayodele

Ravdeep Kaur started working in Decision Resources Inc. as an associate epidemiologist since December 31st, 2015.

She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period.

She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets.

She holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from Rajiv Gandhi University of Health Sciences, India. She also has a Fellowship in Heath care Technology Assessment from World health Organization (WHO), India office.

 Prior to joining Decision Resources, Ravdeep worked as a Consultant in Reproductive, Maternal, Child and Adolescent Health Program in a United States Agency for International development (USAID) funded project.   

Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets.

Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a Ph.D. in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.


Related Reports

Heart Failure - Landscape & Forecast - Disease Landscape & Forecast

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological...

View Details

Chronic Heart Failure | Preserved Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2020

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology...

View Details

Heart Failure - Current Treatment - Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diur...

View Details

Heart Failure | Disease Landscape and Forecast | G7 | 2020

Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates...

View Details